User type: User
Registered: 2021-07-13 15:17:13
The global nanopharmaceutical drugs market is projected to be worth USD 82.71 Billion by 2027, according to a current analysis by Emergen Research. The nanopharmaceutical drugs market is observing high demand attributed to the rising incidence of cancer. Cancer significantly impacts the societal and economic growth in the US and worldwide and is a major contributor to the cost burden of disease. It has been anticipated that 1,806,590 new cancer cases are likely to be diagnosed in the US in 2020, and 606,520 deaths will occur owing to the disease. The advantages offered by nanopharmaceutical drugs comprise targeting lesions/tumor cells, apoptosis commencement, and drug accumulation in specific tissue for improved cancer cells’ exposure cells. Existing pharmaceuticals formulation into the nanoscale has resulted in lower toxicity levels and better cell specificity.
The nanopharmaceutical drugs have been garnering significant market traction due to the ability of such drug systems to overcome restrictions and issues associated with conventional pharmaceutical agents, preparations, and delivery systems. A major concern linked with conventional drug delivery systems is the removal of residual parts of such systems, consequently leaving non-biodegradable substances, which may lead to toxicity issues, in the body of a patient. Also, most of the conventional drug delivery systems have a high initial drug release burst instantly after drug administration, along with low drug solubility.
At Emergen Research, we believe in advancing with technology.
We are a growing market research and strategy consulting company with an
exhaustive knowledge base of cutting-edge and potentially market-disrupting
technologies that are predicted to become more prevalent in the coming decade.